US Pharmacist January 2014 : TIP 1

NOW AVAILABLE Take a bite out of G-CSF acquisition costs * GRANIX ™ is a new option in short-acting G-CSF therapy Announcing J-code J 1446 Effective January 1, 2014 Indication » GRANIX is a leukocyte growth factor indicated for reduction in the duration of severe neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. Important Safety Information » Splenic rupture: Splenic rupture, including fatal cases, can occur following the administration of human granulocyte colony-stimulating factors (hG-CSFs). Discontinue GRANIX and evaluate for an enlarged spleen or splenic rupture in patients who report upper abdominal or shoulder pain after receiving GRANIX. Please see reverse side for additional Important Safety Information and brief summary of Full Prescribing Information on page adjacent to our ad inside. *Based on wholesale acquisition cost (WAC) of all short-acting G-CSF products as of November 11, 2013. WAC represents published catalogue or list prices and may not represent actual transactional prices. Please contact your supplier for actual prices.

Next Page

Publication List
Using a screen reader? Click Here